Biotech company Arovella Therapeutics (ASX: ALA), focused on developing its invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment, has achieved a major milestone. It has completed process development for its patent-protected manufacturing process required for large-scale Good Manufacturing Practice (GMP) manufacturing of its lead product, ALA-101. ALA-101 is an “off-the-shelf” CAR-iNKT cell
Read More
Global molecular diagnostics company Genetic Signatures (ASX: GSS) has decided to halt the development of its EasyScreen Essentials Respiratory Detection Kit for the US market due to increased competition and changing market dynamics. It will now focus its effort and investment on the anticipated launch of the EasyScreen Gastrointestinal Parasite Detection Kit in the US.
Read More
About a third of all food produced is lost or wasted yearly. Besides painting a grim picture of world hunger, this is also responsible for harmful emissions. Tackling food waste, global biotech company Zoono (ASX: ZNO) has teamed up with England-based hygiene tech company OSY to distribute a tech that boosts the shelf-life of produce.
Read More
Melbourne-based therapeutic antibody development company Patrys (ASX: PAB) unveiled positive findings from preclinical studies using PAT-DX1 and PAT-DX3 in animal anti-neutrophil cytoplasmic antibody (ANCA) vasculitis models. Dr Kim O’Sullivan from Monash University presented the findings during the plenary session at the 21st International Vasculitis Workshop in Barcelona. He said, “Both PAT-DX1 and PAT-DX3 are able
Read More
Canadian biotech company Tryp Therapeutics (CSE: TRYP) is set to list on the ASX through a backdoor merger with genetic medicines developer Exopharm (ASX: EX1) in a $14.3 million acquisition agreement. Following this agreement, Exopharm will change its name to Tryp and re-list on the ASX. On completion of the Transaction (Completion), Exopharm will be
Read More
The conversations surrounding artificial intelligence (AI) and its scope to transform the pharma industry have been underway for a while now. In fact, reports suggest that the global health-related AI market is set to be worth $284bn by 2030. Pharmaceutical development company Algorae (ASX: 1AI) is one of the companies at the forefront of this
Read More